|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Cellulitis, pelvic |
|
Endometritis |
|
Infection, bone |
|
Infection, central nervous system |
|
Infection, gynecologic |
|
Infection, intra- abdominal |
|
Infection, joint |
|
Infection, lower respiratory tract |
|
Infection, skin and skin structure |
|
Infection, urinary tract |
|
Meningitis |
|
Peritonitis |
|
Pneumonia |
|
Septicemia |
| |
|
|
SIDE EFFECTS:
|
|
abdominal pain |
|
acute generalized exanthematous pustulosis (AGEP) |
|
agranulocytosis |
|
angioedema |
|
aplastic anemia |
|
asterixis |
|
bronchospasm |
|
candidiasis |
|
cholestasis |
|
colitis |
|
coma |
|
diarrhea |
|
dizziness |
|
elevated hepatic enzymes |
|
encephalopathy |
|
eosinophilia |
|
erythema multiforme |
|
fever |
|
headache |
|
hemolytic anemia |
|
hyperbilirubinemia |
|
hypotension |
|
injection site reaction |
|
jaundice |
|
leukopenia |
|
lymphocytosis |
|
maculopapular rash |
|
myoclonia |
|
nausea/vomiting |
|
neutropenia |
|
pancytopenia |
|
paresthesias |
|
phlebitis |
|
pruritus |
|
pseudomembranous colitis |
|
seizures |
|
Stevens-Johnson syndrome |
|
thrombocytopenia |
|
toxic epidermal necrolysis |
|
urticaria |
|
vaginitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
breast-feeding |
|
children |
|
coagulopathy |
|
colitis |
|
GI disease |
|
intramuscular injections |
|
penicillin hypersensitivity |
|
pregnancy |
|
renal disease |
|
renal failure |
|
renal impairment |
|
|
ADULT DOSE:
|
|
Bone and joint infections-Intravenous, 2 grams (base) every twelve hours .
Intraabdominal infections or
Meningitis or
Pelvic infections, female or
Septicemia-Intravenous, 2 grams (base) every eight hours .
[Melioidosis ] -Intravenous, 120 mg per kg of body weight per day administered every eight hours
Pneumonia, uncomplicated or
Skin and soft tissue infections-Intramuscular or intravenous, 500 mg to 1 gram (base) every eight hours .
Pulmonary infections in cystic fibrosis, due to Pseudomonas -Intravenous, 30 to 50 mg (base) per kg of body weight every eight hours, up to 6 grams per day .
Urinary tract infections, complicated -Intramuscular or intravenous, 500 mg (base) every eight to twelve hours .
Urinary tract infections, uncomplicated -Intramuscular or intravenous, 250 mg (base) every twelve hours .
For all other infections, severe to life-threatening, especially in immunocompromised patients-Intravenous, 2 grams (base) every eight hours .
Note: Adults with renal function impairment may require a reduction in dose. See Ceftazidime Injection USP . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Meningitis-Infants and children 1 month to 12 years of age: Intravenous, 50 mg (base) per kg of body weight every eight hours .
Neonates up to 1 month of age: Intravenous, 25 to 50 mg (base) per kg of body weight every twelve hours .
For all other infections-Infants and children 1 month to 12 years of age: Intravenous, 30 to 50 mg (base) per kg of body weight every eight hours .
Neonates up to 4 weeks of age: Intravenous, 30 mg (base) per kg of body weight every twelve hours .
Note: The safety of the arginine component in the ceftazidime L-arginine formulation has not been established for neonates, infants, or children up to 12 years of age .
If treatment with ceftazidime is indicated, the sodium formulation should be used . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
6 grams (base) per day .
|
|
ELDERLY DOSE:
|
|
Bone and joint infections-Intravenous, 2 grams (base) every twelve hours .
Intraabdominal infections or
Meningitis or
Pelvic infections, female or
Septicemia-Intravenous, 2 grams (base) every eight hours .
[Melioidosis ] -Intravenous, 120 mg per kg of body weight per day administered every eight hours
Pneumonia, uncomplicated or
Skin and soft tissue infections-Intramuscular or intravenous, 500 mg to 1 gram (base) every eight hours .
Pulmonary infections in cystic fibrosis, due to Pseudomonas -Intravenous, 30 to 50 mg (base) per kg of body weight every eight hours, up to 6 grams per day .
Urinary tract infections, complicated -Intramuscular or intravenous, 500 mg (base) every eight to twelve hours .
Urinary tract infections, uncomplicated -Intramuscular or intravenous, 250 mg (base) every twelve hours .
For all other infections, severe to life-threatening, especially in immunocompromised patients-Intravenous, 2 grams (base) every eight hours .
Note: Adults with renal function impairment may require a reduction in dose. See Ceftazidime Injection USP . |
|
|
|
|
|